Literature DB >> 15720090

Stability of foam in sclerotherapy: differences between sodium tetradecyl sulfate and polidocanol and the type of connector used in the double-syringe system technique.

Jaggi Rao1, Mitchel P Goldman.   

Abstract

BACKGROUND: Foam sclerotherapy is an increasingly popular modality in the treatment of varicose veins. Worldwide, the most popular agents used are sodium tetradecyl sulfate (STS) and polidocanol (POL). The double-syringe system technique to make foam out of a sclerosing solution and air has received wide attention for its ease and reproducibility. This study examined the possibility that the relative silicone content of various disposable connectors may affect overall foam stability. We also evaluated the differences in the stability of foam between STS and POL.
MATERIALS AND METHODS: In the first part of the study, one nondisposable stainless steel connector and five disposable plastic connectors were used to create foam from STS 0.50% and air. The procedure was then repeated to produce foam from POL 0.50% and air from each of the six different connector types. As a measure of foam stability, once foam was created with each type of connector, the time required for half of the original volume of sclerosing solution to settle was recorded. In the second part of the study, foam was created with a nondisposable stainless steel connector only and various concentrations of STS and POL. Foam stability was then measured for these different concentrations of sclerosants.
RESULTS: The time for sclerosing solution to settle to half of its initial volume was found to vary according to the specific sclerosant and concentration used, with no statistically significant variation based on connector type.
CONCLUSIONS: The type of connector used in the double-syringe system technique to produce foam for sclerotherapy is not a factor in foam stability. Sclerosing solutions differ in their foaming stability.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15720090     DOI: 10.1111/j.1524-4725.2005.31008

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  5 in total

Review 1.  Polidocanol for endovenous microfoam sclerosant therapy.

Authors:  David M Eckmann
Journal:  Expert Opin Investig Drugs       Date:  2009-12       Impact factor: 6.206

2.  Benefits of polidocanol endovenous microfoam (Varithena®) compared with physician-compounded foams.

Authors:  Dario Carugo; Dyan N Ankrett; Xuefeng Zhao; Xunli Zhang; Martyn Hill; Vincent O'Byrne; James Hoad; Mehreen Arif; David D I Wright; Andrew L Lewis
Journal:  Phlebology       Date:  2015-06-01       Impact factor: 1.740

3.  The role of clinically-relevant parameters on the cohesiveness of sclerosing foams in a biomimetic vein model.

Authors:  Dario Carugo; Dyan N Ankrett; Vincent O'Byrne; David D I Wright; Andrew L Lewis; Martyn Hill; Xunli Zhang
Journal:  J Mater Sci Mater Med       Date:  2015-10-08       Impact factor: 3.896

Review 4.  Endoluminal occlusion devices: technology update.

Authors:  Tobias Zander; Samantha Medina; Guillermo Montes; Lourdes Nuñez-Atahualpa; Michel Valdes; Manuel Maynar
Journal:  Med Devices (Auckl)       Date:  2014-12-01

5.  Effect of Multiple Factors on Foam Stability in Foam Sclerotherapy.

Authors:  Taoping Bai; Wentao Jiang; Yu Chen; Fei Yan; Zhi Xu; Yubo Fan
Journal:  Sci Rep       Date:  2018-10-24       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.